Author Archives: admin


BrainStorm seeks early approval for stem cell treatment in Canada – Fox News

TEL AVIV Israel's BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late-stage clinical trials.

BrainStorm said on Tuesday that it had signed an agreement with CCRM, a Canadian not-for-profit organization that supports development of regenerative medicine, to support a market authorisation request for its ALS treatment, called NurOwn.

CCRM is helping BrainStorm meet requirements for the Canadian health regulator's early access pathway, which provides rapid review for drugs to treat serious or life-threatening conditions.

If NurOwn qualifies, it could be authorized in Canada for distribution by the start of 2018, the company said.

"We seemingly fit the criteria," BrainStorm Chief Executive Chaim Lebovits told Reuters.

At the same time, BrainStorm will conduct a Phase 3 clinical trial for NurOwn at multiple sites in the United States and Israel. The company in December said the advanced clinical trial is expected to begin enrolling patients in the second quarter of 2017.

BrainStorm also plans to submit an application in Israel that will allow patient access to NurOwn as a treatment that has been granted "Hospital Exemption." This recently approved pathway would permit BrainStorm to partner with a medical center in Israel and be allowed to treat patients with NurOwn for a fee.

Lebovits foresees possible treatments under this pathway as early as the second half of 2017.

BrainStorm is also examining whether it may be eligible for early approval in the United States under new legislation passed in December that supporters say will speed access to new drugs.

According to the ALS Association, 5,600 people in the United States are diagnosed each year with the disease, also known as Lou Gehrig's Disease, which has severely disabled British physicist Stephen Hawking.

See the original post here:
BrainStorm seeks early approval for stem cell treatment in Canada - Fox News

Opinion: Oregon patients should beware of stem cell therapy fraud – Portland Business Journal

Opinion: Oregon patients should beware of stem cell therapy fraud
Portland Business Journal
Patients in Oregon seeking accurate information about stem cell therapy have few reliable sources to guide them. It can be hard to separate scientific facts from science fiction. Query Dr. Google and you'll find a slew of clinics and a broad range of ...

Go here to read the rest:
Opinion: Oregon patients should beware of stem cell therapy fraud - Portland Business Journal

Stem cell therapy being used for osteoarthritis – WNDU 16 – WNDU-TV

Osteoarthritis is the most common form of arthritis in the US, affecting nearly twenty-seven million adults. It is currently an incurable disease in which the joints deteriorate. Now, a therapy that has been used in eye surgery and to heal the skin of burn victims is being used for the first time in knees and this new form of treatment involves stem cells from amniotic fluid.

As a professional photographer, climbing up step ladders and walking down stairs are part of the daily grind for 65-year-old Linda Schwartz.

"Theres constant activity; youre moving the whole time, really," said Schwartz.

But the pain of osteoarthritis in both of her knees was making all that activity a little harder.

"Tried cortisone shots. I had, um, something called Euflexxa. I was sent to physical therapy twice. I mean, I did try acupuncture in my knees. But it didnt really seem to make a difference," said Schwartz.

"Its like the rubber on the tire. So as you start to lose the rubber in your tire and the rim hits the road, thats what happens when you have bone on bone arthritis and youve lost all the cartilage in your knee," said dr. Adam Yanke, an orthopedic surgeon at rush university medical center.

Orthopedic surgeon Adam Yanke enrolled Schwartz in an experimental new therapy that involved injecting amniotic fluid that contained stem cells donated by healthy mothers into the knees of osteoarthritis patients.

"Between the two of those theyre a potent anti-inflammatory and they also have growth factors that help promote healing or healthy growth of tissue," said Dr. Yanke.

It was by far the most effective pain treatment that Schwartz has tried and, unlike cortisone shots, there are no side effects. The pain relief has so far lasted up to a year.

"It was a very gradual feeling of its a little bit better, its a little bit better, and then realizing, wow, its really pretty good," said Schwartz.

The one drawback is this therapy is not for patients whose arthritis is so bad it requires knee replacement surgery. Even though its still in the experimental stage, Dr. Yanke offers the stem cell treatment to his patients, but at a cost of 2200 dollars a shot, it is not yet covered by insurance.

TOPIC: Heart Attack: Slashing Door-To-Balloon Times REPORT: MB #4218

BACKGROUND: A heart attack is an event that occurs when the blood flow that transmits oxygen to the heart is severely reduced or stopped completely. One reason for this blood flow to become reduced is because of the blockage of an artery due to fat, cholesterol or plaque. About every 43 seconds, a person in America suffers from a heart attack. The most common symptoms of a heart attack are the following: * Chest discomfort, including uncomfortable pressure, squeezing or pain in the chest that lasts more than a few minutes, or that goes away and later comes back. * Discomfort in other areas of the body, including pain in the arms, back, neck, jaw or stomach. * Shortness of breath. * Cold sweat, nausea and lightheadedness The most common symptom in men is chest pain, whereas women are more likely to experience shortness of breath, vomiting and pain in other parts of the body.

(Source: http://www.heart.org/HEARTORG/Conditions/HeartAttack/AboutHeartAttacks/About-Heart-Attacks_UCM_002038_Article.jsp)

ACTING FAST: Heart attacks are very delicate events, and in order to overcome them it is important to act fast. If you think you are suffering from a heart attack it is important to call 911 immediately in order to be treated as soon as possible in a hospital with treatments like balloon angioplasty, clot-dissolving drugs, surgery and/or a combination of all of the above.

(Source: http://www.heart.org/HEARTORG/Conditions/HeartAttack/TreatmentofaHeartAttack/Treatment-of-a-Heart-Attack_UCM_002042_Article.jsp)

DOOR-TO-BALLOON: In order to save lives it is not only important that the patient acts fast, but the hospital does as well; every minute matters. Normally, severe heart attacks like a STEMI are treated with a door-to-balloon protocol. Door-to-balloon is the time that elapses from when a patient enters the door of the hospital to the time blood flow is circulating to heart again. The American College of Cardiology suggests that this time should be 90 minutes or less. In order for these times to be achieved it is important that everyone involved is working consistently and together; this includes doctors, nurses, paramedics, and pharmacists. There is a checklist these professionals have to follow and the data of each patient is posted daily. The Cleveland Clinic has been able to cut the door-to-balloon time almost in half. Thirty-five percent of their patients have had door-to-balloon times of 45 minutes or less and others were able to be treated in only 21 minutes. Researchers will soon publish the results of how their protocol reduces the overall time and how it is specifically impacting death rates.

(Source: Dr. Travis Gullet & https://consultqd.clevelandclinic.org/2016/05/streamlined-stemi-protocol-slashes-door-balloon-times/)

FOR MORE INFORMATION ON THIS REPORT, PLEASE CONTACT: Andrea Pacetti pacetta@ccf.org

Read more:
Stem cell therapy being used for osteoarthritis - WNDU 16 - WNDU-TV

AgriScience Fair projects range from stem cell research to measuring gluten sensitivities in dogs and humans – Reading Eagle

Every year at the Pennsylvania Farm Show, members of the FFA gather to compete in the AgriScience Fair.

The contest requires that students conduct research and present their findings in ways that help them prepare for their future and develop research skills.

Many students use the program as a part of their Supervised Agricultural Experience, a crucial part of agricultural education that goes along with classroom instruction and FFA involvement. In past years, members of the Conrad Weiser FFA Chapter have excelled in this event at state and national levels, with students placing first, second or third in the nation in a variety of divisions.

Each year brings new students and new opportunities to the AgriScience Fair, which introduced a new division structure for the 2017 competition.

This year, more than 150 students from around the state competed in the AgriScience Fair. Of these, 45 were from the Conrad Weiser FFA, many of them freshmen and first-time competitors.

Students from the Conrad Weiser FFA Chapter were honored for their research in categories ranging from food systems to social systems to environmental and natural resource systems, many of them placing first.

Among those placing first was Adam Zappacosta, a freshman who studied chicken feed as a part of his Animal Systems project. Adam worked on a team with Will Savoy, another freshman, to complete his project and said the AgriScience Fair will benefit him in the future.

Another team representing Conrad Weiser was Rini Kaneria and Lacie Pichler, who studied the effects of antibiotics on the function of murine mesenchymal cells.

Their studies earned them second place in their Animal Systems division.

Kaneria, a junior at Conrad Weiser, was positive about her experiences, even though her team may not be able to go to the national competition.

"I feel as if I learned so much just from doing this project," she said.

Cate Palumbo and Rachel Kesselring, two freshmen, based their project on a topic studied in class, Integrated Pest Management, or IPM.

When asked about the origins of their research, Kesselring said, "This idea was the beginning of our project."

Palumbo added, "The idea for our project happened gradually. We originally liked the idea of doing a project with essential oils, and after some research, we found that essential oils help with pest control."

That line of research led to their project about the effects of peppermint on the muscle tissue and digestive tracts of tobacco hornworms. It earned them first place in the Environmental and Natural Resource Systems division.

"AgriScience showed me that all the scientists who conduct big experiments started somewhere," Palumbo said,

Earning Best in Show and first in his division of Animal Systems with his project about gluten sensitivities was Joseph Gresoi, junior and two-time competitor at the AgriScience Fair.

He started work on his project in 2015, and with the help of some of the science teachers at Conrad Weiser, he shaped his research not only into a science project, but also into countless opportunities.

"The development of this project has been one of the best educational experiences of my life," Gresoi said.

Through his work, he has "had the opportunity to collaborate with scientists across multiple disciplines and learned more than he could have ever hoped for."

Conrad Weiser "Aggies" were full of positive things to say about the FFA AgriScience Fair.

Many are looking into applying for the national competition, which will take place later this year. Among them are Palumbo and Kesselring, Zappacosta and Savoy, and individual competitor Gresoi, who wants to take his project "as far as he can."

As for the rest of the Conrad Weiser FFA Chapter, they cannot wait to see where these scientists go in the future and what wonderful things the future, and their research, bring.

Visit link:
AgriScience Fair projects range from stem cell research to measuring gluten sensitivities in dogs and humans - Reading Eagle

How baseball players are trying stem cells to avoid Tommy John – Yahoo Sports

TEMPE, Ariz. On the day he hoped would save his elbow, Garrett Richards laid face down on a table with his back exposed. A doctor guided a needle into the iliac crest of his pelvic bone and began to extract bone marrow. Richards was wide awake, the blessing of local anesthesia saving him from physical pain but not the anxiety that crept into his head: Is this really going to work?

Within a few minutes, the harvested marrow was hurried to a centrifuge, spun to separate the good stuff, mixed into a slurry of platelet-rich plasma and readied to inject into Richards damaged right elbow. Rather than the standard tear across his ulnar collateral ligament, Richards ran lengthwise along the middle of his UCL, a rare manifestation of an increasingly commonplace injury that almost always ends with Tommy John surgery. Not in this case. While he could have chosen that route, he wanted to explore first the efficacy of the aforementioned good stuff: stem cells.

Today, Garrett Richards is darting 98-mph fastballs again. I feel as good as I ever have throwing a baseball, he said Monday from Tempe Diablo Stadium, where the Los Angeles Angels, perhaps the most Tommy John-addled team in baseball, expect to break camp with Richards as their opening day starter. The 28-year-old is the latest player to turn to orthobiologics, the class of treatments that includes stem cells and PRP, in hopes of healing an injury. While clinical studies have shown great success with those who use orthobiologics, they are not yet a panacea for the pervasive elbow injuries in baseball for two reasons: They work only on partial ligament tears, like Richards, and medical studies have yet to validate their efficacy independent of other treatments run concurrently.

The lack of knowledge as to how orthobiologics work inside the body while the proteins in stem cells and platelets are believed to regrow damaged tissue, doctors have yet to isolate best practices for particular injuries speaks to the difficulties in true medical advances. Still, the desire of Richards and others to avoid surgery lends orthobiologics enough credence to warrant further studies.

I truly think this kind of treatment has significant potential, said Dr. Neal ElAttrache, a longtime orthopedic surgeon at the Kerlan-Jobe clinic in Los Angeles who introduced orthobiologics to Major League Baseball when he injected PRP into the elbow of Dodgers reliever Takashi Saito in 2008. Theres no question biologics are here to stay and biologic manipulation is the frontier of treatment in what were doing. The problem, as I see it, is that the marketing and clinical use has far exceeded the science behind it.

Translation: Once the use of PRP and stem cells found traction in the media, pro athletes and weekend warriors alike sought their use, even if the success stories skewed anecdotal. Bartolo Colon resurrected his career after a stem cell injection in 2010 and is still pitching today at 43. Others did so without the fanfare or publicity. Richards faced a choice after being diagnosed with a partially torn UCL last May: Undergo Tommy John surgery and, at earliest, return following the 2017 All-Star break or follow the advice of Dr. Steve Yoon, a partner of ElAttraches at Kerlan-Jobe, and try to salvage the ligament with stem cells.

Science, bro, Richards said. Im a believer now.

Two weeks before Richards began his treatment, teammate Andrew Heaney had looked to avoid Tommy John via stem cells. Richards figured theyd rehab together every step of the way and be back in time for the fall instructional league. Then at the end of June, a scan showed Heaneys elbow wasnt healing, and he would need reconstructive surgery. Already Tyler Skaggs had taken nearly two years to return from his 2014 surgery, and six weeks after Heaneys, starter Nick Tropeano went down. Like Heaney, he is expected to miss the 2017 season.

It made Richards recovery that much more imperative. His first checkup, six weeks in, showed regrowth in the torn area via ultrasound. By August, he started throwing, and come October, when instructional league was in full bloom, so too was Richards. He didnt hesitate to pump his fastball and rip off one of his spin-heavy breaking balls. As far as pure, raw stuff goes, few in baseball can match Richards.

Read More

He was convinced science was working, bro, though the skepticism about orthobiologics generally remains, and understandably so, in the medical community. In May 2013, a paper published in the American Journal of Sports Medicine found 30 of 34 overhand throwers with partial UCL tears who used PRP had returned to their previous level of competition. This was reason for celebration. If a player could avoid the 14-month-plus recovery from the surgery, better for him as well as the team.

Another study arrived in 2016 that didnt cast doubt on the value of orthobiologics so much as offer a different avenue: rest. The 28 players used everything from electrical stimulation, ultrasound, laser therapy, massage and other soft-tissue work. And when paired with rest, their return to previous level came in at 84 percent. It was almost exactly as effective as PRP.

This reinforced ElAttraches concern: Neither of those studies had a control group against which to measure, so the numbers, while impressive, could not isolate what helped and what didnt. This chicken-or-egg question struck ElAttrache just the same when Saito returned and went on to pitch five seasons.

Maybe it was the injection, ElAttrache said. Or maybe it was that we shut him down and let him heal.

Garrett Richards is darting 98-mph fastballs again after turning to orthobiologics. (Getty Images)

He doesnt know, and thats an important distinction as orthobiologics grows exponentially. In 2004, voters in California pledged to provide $3 billion for stem-cell research and create the California Institute of Regenerative Medicine. It remains a benefactor for an industry trying to find its place in the United States.

Across the world, stem cells have far greater potency. U.S. law prevents doctors from manipulating the cells in any way. They are extracted and put back into patients bodies as is. In Switzerland, for example, doctors will harvest stem cells, manipulate them to promote greater healing capacity and then inject them. At least one star pitcher this offseason sought a stem cell injection in the United States, according to sources, while another veteran traveled halfway across the world to Zurich, seeking the comparative lack of regulations just as Peyton Manning did in 2011 to help heal a neck injury that eventually needed surgery.

The future of orthobiologics domestically doesnt end with the FDA loosening rules on stem cell usage. Doctors see significant promise in stem cells from a babys umbilical cord or a mothers placenta, both of which can be frozen. Already theyre capable of harvesting stem cells from old patients and engineering the cells into an immature state. The possibilities going forward are endless.

For right now, theyre going to play themselves out in Anaheim. The danger zone for re-injury after using orthobiologics tends to fall between April and June, though Richards cant imagine falling prey again. In addition to the 13-week break from throwing he took over the summer, Richards spent 10 more weeks in the offseason letting it heal further.

During his down time, Richards studied his own delivery to find even the slightest inefficiencies. He had three numbers in mind. The first was 85. Thats the percent at which he said hell throw his fastball, though because of improved mechanics he expects it wont hinder his velocity. The second is 100. Thats the pitch limit the Angels will foist on Richards, and hes not one to fight. The third is 200. Thats the number of innings Richards wants to pitch this season. He did it in 2015 and sees no reason he cant again.

If he can throw 85 percent, keep his pitch count below 100 and get those 200 innings, it will play publicly as another validation of orthobiologics. Just the same, if Richards elbow gives out eventually, his association with stem cells could perhaps give those considering it pause. Richards pays no mind to this. He just wants to be great.

So much so, in fact, that its going to cost him. Inside the Angels clubhouse, a chart, labeled 1 through 13, is taped to the side of a locker. Its a list of shame with the price buying lunch for the entire team. Players, coaches, P.R. directors, even manager Mike Scioscia are on there. Next to No. 6, it read: G. Rich Ace. He had made the mistake of saying aloud what he believed to be true: that hes the ace of the Angels.

Fulfilling that depends on plenty of things, none as important as his elbow, and Richards knows that. Hell do everything he can to take care of it, to nurture it, to fight against its natural gift of velocity that puts him at such risk. To make sure that next time hes on a table in the doctors office, its not with his elbow opened up and another season lost.

More on Yahoo Sports: Tom Bradys missing jersey is worth a small fortune Bob Huggins says he fell to his knees because his defibrillator activated Kings GM Vlade Divac says he turned down abetter deal for DeMarcus Cousins Yoenis Cespedes is back with his amazing cars

See more here:
How baseball players are trying stem cells to avoid Tommy John - Yahoo Sports

Blast off: Stem cells from Mayo Clinic physician’s lab launch into space – Medical Xpress

February 19, 2017

Consider it one physician's giant leap for mankind. Today, the latest rocket launch from NASA's Kennedy Space Center in Cape Canaveral, Florida, included a payload of several samples of donated adult stem cells from a research laboratory at Mayo Clinic's Florida campus. The launch by SpaceX, an American aerospace manufacturer and space transport services company, is part of NASA's commercial resupply missions to the International Space Station.

The biological cells come from the laboratory of Abba Zubair, M.D., Ph.D., who says he has eagerly awaited the launch following several delays over the past couple of years. Dr. Zubair, who specializes in cellular treatments for disease and regenerative medicine, hopes to find out how the stem cells hold up in space. He says he's eager to know whether these special cells, which are derived from the body's bone marrow, can be more quickly mass-produced in microgravity and used to treat strokes. Microgravity is the condition in which people or objects appear to be weightless. The effects of microgravity can be seen when astronauts and objects float in space. Microgravity refers to the condition where gravity seems to be very small.

"At Mayo Clinic, research drives everything we do for patients," says Gianrico Farrugia, M.D., vice president, Mayo Clinic, and CEO of Mayo Clinic in Florida. "This space cargo carries important material for research that could hold the key for developing future treatments for strokea debilitating health issue. Research such as this accelerates scientific discoveries into breakthrough therapies and critical advances in patient care."

Dr. Zubair says he has dreamed of this moment all his life, with a passion for space that goes back to his childhood in the northern city of Kano, Nigeria. There, he says he came across a book about the first moon launch and became instantly enthralled. In high school, he recruited other physics students to build a model rocket prototype using corrugated metal and rudimentary materials from the local blacksmith. When it came time to apply for college, however, the school adviser steered him from becoming an astronaut. "He said it may be a long time before Nigeria sends rockets and astronauts into space, so I should consider something more practical," Dr. Zubair recalls.

With the goal of being useful to patients and helping cure disease, he headed to medical school in Nigeria. His training took him to the University of Sheffield, in Sheffield, England; the University of Pennsylvania in Philadelphia; and Harvard University in Cambridge, Massachusetts, as he specialized in bone marrow transplants and stem cell research. He came to Mayo Clinic's Florida campus to treat cancer patients and others whose conditions could be helped by regenerative medicineall the while running a research lab that studies adult stem cells.

Dr. Zubair came across a request for research proposals that involved medicine and outer space four years ago. His mother had died of stroke in 1997, and he had been thinking about stem cells as a treatment for stroke-related brain injury. Collaborating with Mayo Clinic neurologists James Meschia, M.D., and William D. Freeman, M.D., he studied mouse models of stroke.

"Stem cells are known to reduce inflammation," he explains. "We've shown that an infusion of stem cells at the site of stroke improves the inflammation and also secretes factors for the regeneration of neurons and blood vessels."

One big problem is that it may take as many as 200 million cells to treat a human being, and developing vast numbers of stem cells on Earth can take weeks.

"It's further complicated, because some patients are unable to donate cells for themselves, and, sometimes, there aren't enough donors who are a good match, as sometimes occurs for minorities," he says.

Studies in simulators on Earth have shown that adult stem cellsthe undifferentiated cells that exist in the body to replace damaged or dying cellsreproduce quickly and reliably in microgravity. While it's not known why microgravity works better than a petri dish, some researchers speculate the conditions may be similar to the floating environment of developing cells in the body. With funding from the Center for the Advancement of Science in Space, a nonprofit organization, Dr. Zubair hopes to find that, in space, stem cells can be reproduced safely in large quantities, providing new opportunities for patients.

He'll gather real-time information about the cells as astronauts conduct experiments measuring molecular changes.

"We'll be looking to see if there are genes activated in microgravity and analyzing the stages of the cell cycle," he says.

"We may discover proteins or compounds that are produced that we can synthesize on Earth to encourage stem cell growth without having to go to microgravity." Over the last three years of planning, he says he's been tickled to learn about the challenges of space-based research, such as the need for techniques to handle fluids that don't mix in microgravity.

Most importantly, experiments will continue after the expanded stem cells return to Earth.

"We'll study them to make sure they're normal, functional and safe for patients with stroke," he says. "My work in regenerative medicine has always been intentionally translationalnot just to study what the cells do and what can be done with them but to make a difference for patients. That's what makes our project unique."

For the launch, Mayo Clinic is collaborating with the Center for Applied Space Technology (CAST) in Cape Canaveral, and BioServe Space Technologies in Boulder, Colorado. CAST supported Dr. Zubair's research by providing strategic mission planning, proposal development, spaceflight technical support and served as an interface between the research team and various space activities and agencies. BioServe provided space flight hardware, on orbit research protocol and scheduling interface.

Explore further: Researcher to grow human cells in space to test treatment for stroke

Abba Zubair, M.D., Ph.D, believes that cells grown in the International Space Station (ISS) could help patients recover from a stroke, and that it may even be possible to generate human tissues and organs in space. He just ...

Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult ...

A multidisciplinary team of researchers has eliminated fatal mitochondrial DNA mutations in stem cells from patients with mitochondrial diseases. The study is published in a recent online issue of Nature as a collaboration ...

An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy ...

New molecules which scientists hope could one day become drugs for both cancer and diabetes have been created at the University of Bath.

Physicians and patients like to believe that early detection of cancer extends life, and quality of life. If a cancer is present, you want to know early, right? Not so fast.

The community of microorganisms that resides in the gut, known as the microbiome, has been shown to work in tandem with the genes of a host organism to regulate insulin secretion, a key variable in the onset of the metabolic ...

Research from King's College London reveals a new method of repurposing existing drugs as novel treatments for depression, using laboratory studies of brain cells.

Scientists at the University of Washington have discovered that a common type of cell in the vertebrate immune system plays a unique role in communication between other cells. It turns out that these cells, called macrophages, ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:
Blast off: Stem cells from Mayo Clinic physician's lab launch into space - Medical Xpress

R3 Stem Cell Now Offering Regenerative Medicine Treatment in … – PR Web (press release)

Top Stem Cell Therapy in Oklahoma City (844) GET-STEM

Oklahoma City, Oklahoma (PRWEB) February 20, 2017

R3 Stem Cell is now offering regenerative medicine treatment in Oklahoma City with a new Center of Excellence. R3 has partnered with Venturis Clinic, who offers stem cell and PRP therapy along with prolozone treatment by the Board Certified doctors. Call (844) GET-STEM for more information and scheduling.

Stem cell therapy is now mainstream, and helps individuals every day avoid the need for possibly risky surgery. It's helping athletes get back on the field faster, avoid joint replacement and finally achieve pain relief with chronic tendonitis conditions. The regenerative treatments are offered by a Board Certified provider in a contemporary setting.

The stem cell and PRP therapy in Oklahoma City are all outpatient with absolutely minimal risk. Unlike cortisone injections, these treatments actually repair and regenerate cartilage, muscle, bone, tendon, ligament and other damaged tissue.

Minimal down time is necessary after the stem cell therapy in Oklahoma City, which is the opposite of traditional surgery. The treatments contain stem cells, growth factors, concentrated platelets, cytokines and hyaluronic acid. The combination makes for an amazing regenerative environment once injected.

To receive cutting edge regenerative treatment, call Venturis Clinic in Oklahoma City which is now an R3 Stem Cell Center of Excellence at (844) GET-STEM. Also visit https://r3stemcell.com for more information.

Share article on social media or email:

Read more here:
R3 Stem Cell Now Offering Regenerative Medicine Treatment in ... - PR Web (press release)

Iowa GOP takes aim at research – The Daily Iowan

By Sarah Stortz

sarah-stortz@uiowa.edu

Fetal-tissue research could be at risk of being outlawed in Iowa if a bill proposed in the Iowa Senate passes. The human-resource subcommittee of the Iowa Senate, led by Republicans, approved a piece of legislation last week that would prohibit the use of fetal tissue in medical research. This bill would ban receiving or transporting any type of fetal tissue in the state and provide penalties.

It would apply to the University of Iowa medical investigations, one of dozens of universities in the United States using fetal-tissue research.

Iowa City pulmonologist Alan Moy said he supported the bill during its initial hearing because of his opposition to using fetal tissues in research.

I feel that the use is in conflict with medical research and that it defies human research, he said. Federal law doesnt support trafficking on fetal tissue. I disagree with the opponents that this has led to remarkable treatment. Thats wrong. There are more ethical and more superior treatment methods.

Moy said the bills passing should have no effect on the research at the UI.

The law does not prevent buying commercial venues; the abortion clinics just wouldnt be a source, Moy said. There have been a number of cell lines, and they have been created decades ago. You dont need to replenish cell lines with fresh fetal.

On the contrary, Sen. Joe Bolkcom, D-Iowa City, opposed the bill, saying it would do huge damage to the research at universities in Iowa.

Our universities are doing great research with [fetal tissues], but whatever research would have to stop, he said. It could end research for cures and treatments.

Bolkcom said passing the bill passing would be an economically bad decision as well.

Institutions would be put out of business, he said. We cant track the researchers, so they would have to go to other states.

UI immunology Professor Nicholas Zavazava, a researcher, had a mixed opinion.

There are people doing great research with it, but its also a very sensitive issue, he said.

Zavazava works with stem cells at the university and reported that while some work with fetal tissue, its not used often in the research at the UI. Researchers typically use embryonic stem cells.

He said that fetal tissues are distinct from embryonic stem cells, with fetal tissues coming specifically from aborted fetuses.

Alternatively, Zavazava said he wished the school would use different types of methods to avoid controversy, one such being stem-cell transplant.

You can create embryonic stem cells by drawing your own blood. There would be no fetus involved, he said. Unfortunately, this costs a lot of money, and Iowa just never invested in it. I really hope that Iowa would embrace it more.

This is the second time members of the Senate have tried to pass a bill that would restrict fetal tissue used in medical research, with a very similar bill proposed last year that passed in the Iowa House.

Bolkcom said he urges anyone who doesnt want this bill to pass, follow through by calling their senators.

Now that Republicans are in charge, theres a pretty decent chance of this passing, he said.

See the original post here:
Iowa GOP takes aim at research - The Daily Iowan

Stem Cell Transplants May Help Some With Multiple Sclerosis – The Tand D.com

MONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.

Specifically, younger patients with a relapsing form of MS who were not severely disabled and who hadn't found relief with other treatments fared better than others over five years, the international team of researchers found.

However, in some cases the treatment proved fatal, the researchers reported.

"Stem cell transplantation cannot be considered a cure for MS. However, it can be considered a concrete option for patients showing aggressive MS who have not responded to approved treatments," said study co-author Dr. Riccardo Saccardi. He's from the cell therapy and transfusion medicine unit at Careggi University Hospital in Florence, Italy.

Using patients' own stem cells to reboot the immune system is a way to halt the advance of the disease. But the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.

In fact, nearly 3 percent of the patients died shortly after receiving the transplant, and those deaths were directly related to the transplant, the researchers reported.

Those deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.

In effect, those patients gambled with a treatment that could be fatal for a disease that isn't, said Dr. Michael Racke, a professor in the department of neurology at Ohio State University.

Racke pointed out that stem cell transplants were first used to treat deadly diseases, such as leukemia, lymphoma and other cancers.

"There may be a population of MS patients that could be identified that might do well with transplant," he said. "It's important to select patients in such a way that they actually get well with the transplant."

A trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.

More than 2 million people in the world suffer from MS, in which the body attacks the central nervous system, according to the National Multiple Sclerosis Society.

MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.

These symptoms can come and go, or persist and worsen over time. Most people are diagnosed between the ages of 20 and 50, although individuals as young as 2 and as old as 75 have developed the disease, the society says.

Medications can slow the progression of MS and help patients manage symptoms, but there's no cure.

To see how patients did over the long term after stem cell transplants, Saccardi and colleagues followed 281 patients from 13 countries who received stem cell transplants between 1995 and 2006.

The researchers found that 46 percent of the patients experienced progression-free survival at five years after transplant.

Within 100 days of transplant, however, eight patients died (nearly 3 percent). Those deaths were related to the transplants, Saccardi said.

The researchers think these deaths were most likely due to the transplant technology used before 2006, which has since improved.

The report was published online Feb. 20 in the journal JAMA Neurology.

Dr. Paul Wright is chair of neurology at North Shore University Hospital in Manhasset, N.Y., and Long Island Jewish Medical Center, in New Hyde Park, N.Y. He said, "As neurologists battle with current therapies that are limited for progressive MS in younger patients, this study provides a possible new avenue for treatment."

See the rest here:
Stem Cell Transplants May Help Some With Multiple Sclerosis - The Tand D.com

Here’s Why Organoids Are a Game Changer in Medical Research – Newsweek

This article was originally published on The Conversation. Read the original article.

Most of the research behind new medical advances is carried out using either animal tissues or cancer cells. Both tools have their problems: results from animals and humans do not always match up and cancer cells grown for years in laboratories often do not mimic the tissues they originally came from very well. Bridging the gap between whole animals and simple cells can be a challenge during the development of new treatments, but this is beginning to change since scientists have learned how to grow organoids.

Organoids are clusters of cells that organize themselves into mini versions of our organs. They are grown from stem cells, and their use has only become possible with the discovery of the precise conditions needed to keep stem cells alive outside the body. Organoids were first made from intestines but have since been made using many other tissues, including liver, breast and even brain cells. This will allow scientists to better study the development and diseases of these organs.

Try Newsweek for only $1.25 per week

An engineer from CNRS (French Reseach Institut Center) introduces embryonic stem cells in a mouse embryo to set a genetically modified line, Marseille, France, February 9, 2012. Organoidslab-grown miniature versions of organsare proving to be a game changer in the field of medical research. Anne-Christine Poujoulat/AFP/Getty Images

They are grown in a gel that allows them to develop three-dimensionally, so they mimic the architecture of our organs much more realistically than a simple layer of cells. Stem cells from the intestine multiply to form a ball, in which the hollow centeris like the space inside the intestine. The surface of these balls then buds outwardat various points to form pocket-like extensions. This is similar to the intensely folded surface of the gut wall.

Organoids have several advantages over existing approaches. Stem cells are taken from animals or patients and continually multiply so the organoids can be maintained for months. They provide an unlimited supply of material for study, meaning fewer animal studies are required. Making organoids from patients also raises intriguing possibilities for personalized medicine.

In traditional cell cultures every cell is identical but stem cells can form many different cell types, so organoids contain a much more realistic mixture of cells. For example, M cells are specialized cells in the gut wall that act as surveillance posts, capturing bacteria from the gut and showing them to the immune system so it can monitor for danger. Some harmful bacteria exploit this to invade the gut wall. It was previously tricky to grow M cells in the lab for study, but they can be grown in organoids. When added to organoids, Salmonella, a bacterium that causes food poisoning, infected M cells more often than other cell types, suggesting this may be a route of infection in humans.

Some common disease-causing bacteria are surprisingly difficult to grow in the lab, making them hard to study. Clostridium difficile causes numerous cases of diarrhoea every year, a serious condition in frail patients. It has been difficult to grow C. difficile because it requires conditions without oxygen, but researchers in the U.S. have shown that the bug can survive inside intestinal organoids. Bacteria were injected into the centerof intestinal organoids and produced a toxin that made the organoid wall leakier, damaging its ability to act as a barrier.

Organoids made from patient biopsies are allowing us to investigate differences between individuals. Patients with cystic fibrosis show varied responses to treatments. One group of researchers grew organoids from patient biopsies and tested their response to different combinations of drugs. In the future this may be used to quickly find the best treatment for each individual.

Tumors also vary hugely between individuals. Dutch researchers grew organoids from patients with colorectal tumors and identified genetic changes that had occurred in the tumour cells compared to the patients healthy tissue. They were then able to see how these altered the way the cells behaved. They tested anti-cancer drugs on the organoids and could tell which drugs did and did not kill the tumor cells.

Imagine if organoids were routinely made from tumor biopsies and used to identify the best chemotherapy combination for each patient. This is certainly plausible, but the process will first need to be made quicker and cheaper.

All this makes organoids an exciting new tool for researchers. Most work currently focuses on the stomach and intestine, but the technique is quickly expanding to other tissues, such as liver, breast and brain. Organoids will transform the way we conduct medical research, from basic understanding to drug development and personalized therapies. Expect to hear much more about them in the future.

Louise ThompsonisPhD candidate in Molecular and Cellular Physiology at theUniversity of Liverpool.

See original here:
Here's Why Organoids Are a Game Changer in Medical Research - Newsweek